08:16 AM EDT, 05/07/2024 (MT Newswires) -- Intra-Cellular Therapies ( ITCI ) reported a Q1 net loss Tuesday of $0.16 per diluted share, narrower than its loss of $0.46 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.33.
Net total revenue for the biopharmaceutical company for the quarter ended March 31 was $144.9 million, up from $95.3 million a year earlier.
Analysts surveyed by Capital IQ expected $141.4 million.